ClinicalTrials.gg
CompletedNCT04406896Updated Jul 4, 2025

The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics

A Phase 1 interventional study of Selatogrel in Healthy Subjects and Hepatic Impairment, sponsored by Viatris Innovation GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of mild and moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of selatogrel (ACT-246475).

02

Conditions studied

  • Healthy Subjects
  • Hepatic Impairment
03

In context

Lead sponsor

Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants (Groups 1,2 and 3)

  • Signed in a language understandable to the participant prior to any study-mandated procedure.
  • Male or female participant aged between 18 and 79 years (inclusive) at screening.
  • of 18.0 to 35.0 kg/m2 (inclusive) at screening.
  • Women of must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 (pre-dose). They must consistently and correctly use (from screening, during the entire study, and for at least 30 days after last study treatment administration) an acceptable effective method of method, be sexually inactive, or have a vasectomized partner. If a hormonal contraceptive is used, it must have been initiated at least 1 month before treatment administration.
  • Women of non-childbearing potential.

Additional principal inclusion criteria for participants with hepatic impairment (Groups 1 and 2)

  • Hepatic impairment due to liver cirrhosis according to the classification:

    • Group 1: Mild hepatic impairment, Child-Pugh A = score 5-6.
    • Group 2: Moderate hepatic impairment, Child-Pugh B = score 7-9.
  • Systolic blood pressure (SBP) 95-160 mmHg, diastolic blood pressure (DBP) 60-95 mmHg, and pulse rate 50-100 bpm (inclusive), measured on the same arm, after 5 minutes in the supine position at screening and on Day 1 (pre-dose).
  • Estimated (eGFR) at screening using the Modification of Diet in Renal Disease (MDRD) formula of:

    • greater than or equal to 60 mL/min/1.73 m2 for participants with mild hepatic impairment (Group 1)
    • greater than or equal to 45 mL/min/1.73 m2 for participants with moderate hepatic impairment (Group 2).
  • Stable concomitant medications for at least 3 weeks prior to screening and up to Day 1 and expected to be stable during the conduct of the study.

Additional principal inclusion criteria for healthy participants (Group 3)

  • Normal blood pressure measured on the same arm, after 5 minutes in the supine position at screening and on Day 1 pre-dose defined as:

    • SBP 90 to 140 mmHg, DBP 60 to 90 mmHg, and pulse rate 50 to 100 bpm (inclusive) for participants less than 60 years of age.
    • SBP 95 to 160 mmHg, DBP 65 to 95 mmHg, and pulse rate 50 to 100 bpm (inclusive) for participants 60 years and older.
  • eGFR greater than or equal to 80 mL/min/1.73 m2 at screening using the MDRD formula.

Exclusion criteria

Exclusion Criteria:

All participants (Groups 1, 2 and 3)

  • Pregnant or lactating woman.
  • Previous exposure to selatogrel.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • Known to P2Y12 receptor antagonists or any of the drug formulation.
  • Known disorders.
  • Legal incapacity or limited legal capacity at screening.

Additional exclusion criteria for participants with hepatic impairment (Groups 1 and 2)

  • History or clinical evidence of any disease and/or existence of any surgical or medical condition (e.g., cholecystectomy), which might interfere with the absorption, distribution, metabolism, and excretion (ADME) of the study treatment (except for hepatic impairment, appendectomy, and herniotomy).
  • Acute hepatitis, hepatic cancer, primary biliary cirrhosis, or any form of cholestatic disease.
  • Clinical evidence or suspected acute liver failure as judged by the investigator.
  • Severe ascites and/or pleural effusion.
  • Encephalopathy greater than grade 2.
  • Clinical evidence of current alcohol or drug abuse.
  • abnormalities on a 12-lead , except for abnormalities related to hepatic impairment, after 5 minutes in the supine position at screening and on Day 1 pre-dose.

Additional exclusion criteria for healthy participants (Group 3)

  • History or clinical evidence of any disease and/or existence of any surgical or medical condition (e.g., cholecystectomy), which might interfere with the ADME of the study treatment (except for appendectomy and herniotomy).
  • History or clinical evidence of alcohol or drug abuse within the 3 years prior to screening.
  • Family or personal history of prolonged bleeding or bleeding disorders, intracranial vascular diseases, stroke, reasonable suspicion of vascular malformations, or peptic ulcers.
  • Previous treatment with any prescribed medications or over-the-counter medications within 2 weeks or 5 times the terminal half-life (t½), whichever is longer prior to study treatment administration (excludes and hormone replacement therapy).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Participants with mild hepatic impairment (Group 1)

    Participant with Child-Pugh Grade A Score of 5-6.

    Drug: Selatogrel

  • Experimental
    Participants with moderate hepatic impairment (Group 2)

    Participant with moderate hepatic impairment with a Child-Pugh Grade B Score of 7-9.

    Drug: Selatogrel

  • Experimental
    Healthy participants (Group 3)

    Drug: Selatogrel

Interventions

  • A single subcutaneous injection of 16 mg.

    Also known as: ACT-246475

06

What researchers measure

Primary outcomes

  1. The maximum plasma concentration (Cmax) of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  2. Time to reach Cmax (tmax)

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  3. Area under the plasma concentration-time curves (AUC0-t) of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  4. The area under the plasma concentration-time curve from zero to infinity (AUC0-inf) of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  5. Terminal half-life (t½) of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  6. The apparent clearance (CL/F) of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  7. The apparent volume of distribution (Vz/F) of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 3.

  8. Plasma protein binding of selatogrel

    Time frame: Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose and post-dose).

Secondary outcomes

  1. Change from baseline in supine blood pressure

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  2. Change from baseline in temperature

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  3. Change from baseline in pulse rate

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  4. Change from baseline in body weight

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  5. Change from baseline in clinical laboratory tests

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  6. Change from baseline at each time point of measurement in ECG variables.

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

  7. Inhibition of platelet aggregation

    Time frame: Multiple predefined times on Day 1 (pre-dose) up to Day 3.

07

Study locations

1 site
  • CRS Clinical Research Services
    Kiel, 24105, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Oct 2020, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2020
First posted
May 29, 2020
StartActual
Jul 22, 2020
Primary completionActual
Oct 23, 2020
CompletionActual
Oct 23, 2020
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04406896
Responsible party
Sponsor
First posted
May 29, 2020
Start date
Jul 22, 2020
Primary completion
Oct 23, 2020
Completion
Oct 23, 2020
Last update
Jul 4, 2025

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selatogrel

Start the discussion